Compares apixaban with warfarin to prevent clots in people with a heart pump
Tests apixaban against warfarin in adults with heart failure and a heart pump.
Plain-language title generated from the registry record
Registry title: SWITCH: Apixaban vs Vitamin K in HM3
Key facts
- Where
- New York, United StatesSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07471139, who can take part
Where in United States
- Columbia University Irving Medical CenterNew York, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Columbia University
- Trial code
- NCT07471139
- Record updated
- 4 November 2026
- Original description
This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced heart failure who are chronically supported by a HeartMate 3 Left Ventricular Assist Device for 3 months.Read full original descriptionShow less
The SWITCH Trial: A Randomized Controlled Study of Apixaban Versus Vitamin K Antagonists in Patients With HeartMate 3 Left Ventricular Assist Devices
This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced heart failure who are chronically supported by a HeartMate 3 Left Ventricular Assist Device for 3 months.
Inclusion: Participants will have HeartMate3 LVAD implanted > 3 months before enrollment; ≥ 18 years old; Treated with WARFARIN SODIUM; Participant must provide written informed consent prior to any clinical investigation related procedure; In female participants of childbearing capability, not currently pregnant and on appropriate contraception.
Exclusion: Bridge to transplant; Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results; Known allergy to Apixaban; Severe renal dysfunction Estimated Glomerular Filtration Rate (eGFR) <20; History of major bleeding event with subsequent reduction of INR goal to < 1.8; Apixaban dose reduction criteria (Age ≥80 years, weight ≤60 kg, creatinine ≥1.5 mg/dL); Participation in any other clinical investigation(s) involving a Mechanical Circulatory Support (MCS) device, or interventional investigation(s) likely to confound study results or affect study outcome; Aortic root thrombus.